MicroRNAs As Novel Biomarkers and Potential Therapeutic Options for Inflammatory Cardiomyopathy
ESC Heart Failure · 2023
DOI: 10.1002/ehf2.14523 ↗Kurz gefasst
Fachartikel in der Zeitschrift ESC Heart Failure, 2023. Verfasst von Ganna Aleshcheva und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Cardiac Diagnostics and Therapy (IKDT), Moltkestr. 31, Berlin, Germany. Hauptthemen laut MEDLINE: MicroRNAs, Myocarditis, Cardiomyopathy, Dilated, Heart Failure. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: EFRE, European Regional Development Fund.
Abstract (Originalsprache)
Aims
Inflammation of the heart is a complex biological and pathophysiological response of the immune system to a variety of injuries leading to tissue damage and heart failure. MicroRNAs (miRNAs) emerge as pivotal players in the development of numerous diseases, suggesting their potential utility as biomarkers for inflammation and as viable candidates for therapeutic interventions. The primary aim of this investigation was to pinpoint and assess particular miRNAs in individuals afflicted by virus-negative inflammatory dilated cardiomyopathy (DCMi). Methods and results The study involved the analysis of 152 serum samples sourced from patients diagnosed with unexplained heart failure through endomyocardial biopsy. Among these samples, 38 belonged to DCMi patients, 24 to DCM patients, 44 to patients displaying inflammation alongside diverse viral infections, and 46 to patients solely affected by viral infections without concurrent inflammation. Additionally, serum samples from 10 healthy donors were included. The expression levels of 754 distinct miRNAs were evaluated using TaqMan OpenArray. MiR-1, miR-23, miR-142-5p, miR-155, miR-193, and miR-195 exhibited exclusive down-regulation solely in DCMi patients (P < 0.005). These miRNAs enabled effective differentiation between individuals with inflammation unlinked to viruses (DCMi) and all other participant groups (P < 0.005), boasting a specificity surpassing 86%.
Conclusions
The identification of specific miRNAs offers a novel diagnostic perspective for recognizing intramyocardial inflammation within virus-negative DCMi patients. Furthermore, these miRNAs hold promise as potential candidates for tailored therapeutic strategies in the context of virus-negative DCMi.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Cardiac Diagnostics and Therapy (IKDT), Moltkestr. 31, Berlin, Germany.
- Division of Viral Gastroenteritis and Hepatitis Pathogens and Enteroviruses, Department of Infectious Diseases, Robert Koch Institute, Berlin, Germany.
- Department of Cardiology, Campus Virchow, Charité - University Hospital Berlin, Berlin, Germany.
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany.
Förderung
- EFRE
- European Regional Development Fund
Zitieren
APA
Aleshcheva, G., Baumeier, C., Harms, D., Bock, C. T., Escher, F., & Schultheiss, H. P. (2023). MicroRNAs As Novel Biomarkers and Potential Therapeutic Options for Inflammatory Cardiomyopathy. ESC Heart Failure. https://doi.org/10.1002/ehf2.14523
Vancouver
Aleshcheva G, Baumeier C, Harms D, Bock CT, Escher F, Schultheiss HP. MicroRNAs As Novel Biomarkers and Potential Therapeutic Options for Inflammatory Cardiomyopathy. ESC Heart Failure. 2023. doi:10.1002/ehf2.14523
BibTeX
@article{Aleshcheva2023,
author = {Aleshcheva, Ganna and Baumeier, Christian and Harms, Dominik and Bock, C-Thomas and Escher, Felicitas and Schultheiss, Heinz-Peter},
title = {MicroRNAs As Novel Biomarkers and Potential Therapeutic Options for Inflammatory Cardiomyopathy},
journal = {ESC Heart Failure},
year = {2023},
doi = {10.1002/ehf2.14523}
}
EUVIMED